These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15015890)

  • 1. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
    Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):3-7. PubMed ID: 15015890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.
    Dimopoulos MA; Anagnostopoulos A
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):8-16. PubMed ID: 15015891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
    Rajkumar SV
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):17-22. PubMed ID: 15015892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
    Barlogie B
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose thalidomide in patients with relapsed or refractory multiple myeloma.
    Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H
    Leuk Lymphoma; 2003 Nov; 44(11):1943-6. PubMed ID: 14738147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.
    Alexanian R; Weber D; Giralt S; Delasalle K
    Ann Oncol; 2002 Jul; 13(7):1116-9. PubMed ID: 12176792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and dexamethasone combination for refractory multiple myeloma.
    Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N
    Ann Oncol; 2001 Jul; 12(7):991-5. PubMed ID: 11521808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
    Steurer M; Spizzo G; Mitterer M; Gastl G
    Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
    Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide and dexamethasone for resistant multiple myeloma.
    Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R
    Br J Haematol; 2003 Jun; 121(5):768-71. PubMed ID: 12780791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
    Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G
    Clin Lymphoma; 2003 Jun; 4(1):32-5. PubMed ID: 12837152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of immunomodulatory drugs in multiple myeloma.
    Anderson KC
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):23-32. PubMed ID: 15015893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.
    Jo JC; Kang BW; Sym SJ; Lee SS; Jang G; Kim S; Lee DH; Kim SW; Lee JS; Suh C
    Invest New Drugs; 2011 Feb; 29(1):175-81. PubMed ID: 19823768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future role of thalidomide in multiple myeloma.
    Boccadoro M; Blade J; Attal M; Palumbo A
    Acta Haematol; 2005; 114 Suppl 1():18-22. PubMed ID: 16166768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
    Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R
    J Clin Oncol; 2003 Jan; 21(1):16-9. PubMed ID: 12506164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
    Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
    Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.